Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
| العنوان: | Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom |
|---|---|
| المؤلفون: | Andy Garnham, K. Maman, Samuel Aballéa, Zalmai Hakimi, Isaac Odeyemi, Mondher Toumi, Jameel Nazir, K. Thokagevistk |
| المصدر: | Clinical Drug Investigation |
| بيانات النشر: | Springer Science and Business Media LLC, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Adult, medicine.medical_specialty, Tolterodine Tartrate, Cost effectiveness, Cost-Benefit Analysis, Phenylpropanolamine, Urology, urologic and male genital diseases, Cresols, Double-Blind Method, Humans, Medicine, Pharmacology (medical), Original Research Article, Benzhydryl Compounds, Oxybutynin, Urinary bladder, Solifenacin, Urinary Bladder, Overactive, business.industry, General Medicine, medicine.disease, United Kingdom, humanities, female genital diseases and pregnancy complications, Thiazoles, medicine.anatomical_structure, Overactive bladder, Quality of Life, Urological Agents, Acetanilides, Tolterodine, business, Mirabegron, medicine.drug |
| الوصف: | Background Overactive bladder (OAB) is highly prevalent and is associated with considerable morbidity and reduced health-related quality of life. β3-adrenergic receptor (β3-AR) stimulation is a novel alternative to antimuscarinic therapy for OAB. Objective The objective of this analysis was to assess the cost effectiveness of the β3-AR agonist mirabegron relative to tolterodine extended release (ER) in patients with OAB from a UK National Health Service (NHS) perspective. Methods A Markov model was developed to simulate the management, course of disease, and effect of complications in OAB patients over a period of 5 years. Transition probabilities for symptom severity levels and probabilities of adverse events were estimated from the results of the randomised, double-blind SCORPIO trial in 1,987 patients with OAB. Other model inputs were derived from the literature and on assumptions based on clinical experience. Results Total 5-year costs per patient were £1,645.62 for mirabegron 50 mg/day and £1,607.75 for tolterodine ER 4 mg/day. Mirabegron was associated with a gain of 0.009 quality-adjusted life-years (QALYs) with an additional cost of £37.88. The resulting incremental cost-effectiveness ratio (ICER) was £4,386/QALY gained. In deterministic sensitivity analyses in the general OAB population and several subgroups, ICERs remained below the generally accepted willingness-to-pay (WTP) threshold of £20,000/QALY gained. The probability of mirabegron 50 mg being cost effective relative to tolterodine ER 4 mg was 89.4 % at the same WTP threshold. Conclusions Mirabegron 50 mg/day is likely to be cost effective compared with tolterodine ER 4 mg/day for adult patients with OAB from a UK NHS perspective. Electronic supplementary material The online version of this article (doi:10.1007/s40261-014-0240-z) contains supplementary material, which is available to authorized users. |
| تدمد: | 1179-1918 1173-2563 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb15698e105f68bbcec37e24543f2d45Test https://doi.org/10.1007/s40261-014-0240-zTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....bb15698e105f68bbcec37e24543f2d45 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 11791918 11732563 |
|---|